Target of Interest
Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Application
图: 1 / 2
Golimumab Antibody (MA5-41795) in ELISA
Direct ELISA results against the Human TNFa/TNF-alpha protein using a Golimumab biosimilar monoclonal antibody (Product # MA5-41795) at a dilution of 1:5,000-1:10,000.
产品信息
MA5-41795
产品规格
种属反应
Human
宿主/亚型
Human
/ IgG1, kappa
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
抗原
Human TNFA/TNF alpha
偶联物
Unconjugated
形式
Liquid
浓度
2.8 mg/mL
纯化类型
Protein A
保存液
PBS, pH 7.5
内含物
no preservative
保存条件
-20°C, Avoid Freeze/Thaw Cycles
运输条件
Ambient (domestic); Wet ice (international)
RRID
AB_2910938
产品详细信息
Endotoxin level < 0.01EU/µg by LAL method
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
靶标信息
Golimumab is a human IgG1kappa monoclonal antibody derived from immunizing genetically engineered mice with human TNFalpha. Golimumab binds and inhibits soluble and transmembrane human TNFalpha. Increased TNFalpha is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U. S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed. As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFalpha. Inhibition of TNFalpha prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
